Evolus (NASDAQ:EOLS) Price Target Raised to $15.00

Posted by Geri Gentry on Nov 5th, 2026

Evolus (NASDAQ:EOLS – Get Free Report) had its price target lifted by analysts at BTIG Research from $13.00 to $15.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. BTIG Research‘s target price would suggest a potential upside of 100.80% from the stock’s previous close.

A number of other equities analysts have also recently issued reports on EOLS. Weiss Ratings reiterated a “sell (d-)” rating on shares of Evolus in a research note on Friday, September 11th. HC Wainwright reissued a “buy” rating and set a $13.00 price target on shares of Evolus in a research report on Tuesday, August 25th. Finally, Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a report on Saturday, August 8th. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, Evolus currently has an average rating of “Moderate Buy” and a consensus price target of $15.00.

Check Out Our Latest Stock Analysis on Evolus

Evolus Stock Up 1.4%

EOLS stock opened at $7.47 on Thursday. The business has a 50 day moving average of $7.89 and a 200 day moving average of $6.29. The firm has a market cap of $493.39 million, a PE ratio of -14.37 and a beta of 1.38. Evolus has a twelve month low of $3.86 and a twelve month high of $9.31.

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 105,108 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $9.04, for a total transaction of $950,176.32. Following the sale, the insider owned 499,592 shares of the company’s stock, valued at $4,516,311.68. This trade represents a 17.38% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 5.00% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in EOLS. GAMMA Investing LLC lifted its holdings in Evolus by 65.6% in the third quarter. GAMMA Investing LLC now owns 3,288 shares of the company’s stock valued at $26,000 after acquiring an additional 1,303 shares during the period. China Universal Asset Management Co. Ltd. grew its stake in shares of Evolus by 15.0% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,052 shares of the company’s stock valued at $96,000 after purchasing an additional 1,571 shares during the period. Krilogy Financial LLC increased its position in shares of Evolus by 20.0% during the 3rd quarter. Krilogy Financial LLC now owns 13,907 shares of the company’s stock valued at $108,000 after purchasing an additional 2,320 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Evolus in the 3rd quarter worth approximately $27,000. Finally, Bank of New York Mellon Corp lifted its stake in shares of Evolus by 3.9% in the 1st quarter. Bank of New York Mellon Corp now owns 143,164 shares of the company’s stock worth $588,000 after purchasing an additional 5,367 shares during the period. Institutional investors own 90.69% of the company’s stock.

Evolus Company Profile

(Get Free Report)

Evolus, Inc is a commercial-stage medical aesthetics company focused on developing and marketing products for physicians and other licensed aesthetic providers. The company’s business is centered on minimally invasive treatments intended to address facial lines, wrinkles and other visible signs of aging.

Evolus’ primary product is Jeuveau (prabotulinumtoxinA-xvfs), an injectable botulinum toxin approved by the U.S. Food and Drug Administration for the temporary improvement of moderate to severe glabellar lines, commonly known as “frown lines,” in adults.